Cannabis Investments

Cannabis Science in Final Negotiations to Purchase 50% of what will be a 10,000 Square Foot Cancer Centre in Arizona With Over 500 Existing Medical Cannabis Patients

April 18, 2012

COLORADO SPRINGS, Colo.–(BUSINESS WIRE)–Cannabis Science, Inc. (OTCBB: CBIS.OB – News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to announce we are in final negotiations to purchase 50% of a 10,000 square foot Cancer Centre in Arizona. This Cancer Centre already has 500 existing patients with new patients inquiring daily, from around the world, looking for cannabis-based treatments for numerous critical ailments.

Cannabis Science expects to sign the deal for the Cancer Centre within the next few days. We will release detailed information regarding purchase to our shareholders and the general public. First and foremost, Cannabis Science is a patient orientated company. This acquisition will expand our patient support. With our on site oncologist and radiologist, we will medically document patient outcomes.

The 10,000 square foot building features 20 clinic rooms for those new and existing patients. There will be an onsite physician to guide them and suggest the appropriate treatment package. This Cancer Centre is equipped to operate as a full service medical cannabis treatment center, including a lab for clinical testing. Incoming patients will first get an assessment and when necessary, an x-ray or MRI. There will also be a separate specialized doctor on site, who can issue an MMC card to incoming patients who do not already have one. Additionally, as part of this joint venture, Cannabis Science will have associated local dispensaries and labs for testing.

This Cancer Centre will allow new and existing patients to seek professional help and assistance, while assisting patients to self-administer treatments for different ailments including: AIDS, Alzheimers, Anti-Aging, Autism, Asthma, Arthritis, Auto Immune Disease, Brain Trauma (Closed Head Injury), Cancer, Chronic Pain Management, Crohn’s, Irritable Bowel Syndrome (IBS), Diabetes, Digestive Illnesses, Gastro Intestinal Reflux Disease (GERD), Glaucoma, High Blood Pressure, Influenza, Methicillin-Resistant Staphylococcus Aureus (MRSA), Multiple Sclerosis (MS), Post Traumatic Stress Disorder (PTSD) and Tourette Syndrome.

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO
1-888-889-0888
info@cannabisscience.com
www.cannabisscience.com
or
Robert Kane
VP Investor Relations
1-561-234-6929
rkane@cannabisscience.com
info@cannabisscience.com
www.cannabisscience.com

View full post on News Releases

Chronic Future: Killing Cancer Premiered on April 5; Cannabis Science’s CEO Dr. Robert Melamede and Filmmaker Henry Miller Weigh in on Its Success

April 12, 2012

COLORADO SPRINGS, Colo.–(BUSINESS WIRE)–Cannabis Science, Inc. (OTCBB: CBIS.OB – News), a pioneering US biotech company developing pharmaceutical cannabis products, is thrilled to provide an update on the premiere of Chronic Future: Killing Cancer, a film by Henry Miller and Cory Pritchard. It tells the story of the attempt by Arizona’s governor to close down medical marijuana dispensaries, and introduces patient after patient, with debilitating ailments, where medical marijuana has successfully treated the disease. Cannabis Science’s CEO, Dr. Robert Melamede, was interviewed for the film about the success the company has seen with patients self-administering cannabis oil to their squamous cell carcinomas, and reducing their tumor burden, even apparently eradicating tumors as determined by biopsy.

The film premiered April 5, 2012 in Scottsdale, Arizona, followed by 3 showings per day. The first five showings were sold out, with the following ones close to sold out. Henry Miller states, “There were over 3,500 people who showed up for tickets throughout the day. We got 3 standing ovations for the very first showing. Every state that has legal medical marijuana is part of our formula to fight for federal justice and their acknowledgement of scientific reality. We touched every state. I’m getting calls from people all over the world asking how they can get the film. I haven’t had one negative response. [Dr. Melamede] is a genuine, sincere person; a beautiful soul. We couldn’t ask for a better doctor to be representing this.” Miller has received calls from Japan, China, India, Russia, Great Britain, Germany, Australia, South Africa, France, and Canada.

In addition to the 3,500 viewers who showed up for tickets, the movie has caught the attention of celebrities such as Angelina Jolie. Miller has “tweeted with Angelina Jolie, who saw the clips, and says she hopes it will end world hunger.” Henry Miller hopes to be interviewed by Howard Stern, 60 Minutes, Good Morning America, Anderson Cooper, John Stewart, Oprah, David Letterman, and Jimmy Kimmel, just to name a few. Miller says, “The celebrities are coming out and seeing what we’re doing, and are willing to help us and support us.”

Dr. Robert Melamede commented, “As evidenced by the demographics of the population attending the opening, it’s quite apparent that medical marijuana has moved out of the counterculture and into the mainstream of well to do American citizens. People have already contacted me about the availability of our treatment for skin cancer.”

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888
President & CEO
info@cannabisscience.com
www.cannabisscience.com
or
Robert Kane, 1-561-234-6929
VP Investor Relations
rkane@cannabisscience.com
info@cannabisscience.com
www.cannabisscience.com

View full post on News Releases

Cannabis Science Reports Second Cancer Patient Receives Clean Biopsy Report Confirming the Biopsy is Free of Cancer Cells

April 4, 2012

COLORADO SPRINGS, Colo.–(BUSINESS WIRE)– Cannabis Science, Inc. (OTCBB: CBIS.OB – News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products is happy to report that patient #2, who had a Squamous cell carcinoma on her arm, has received her biopsy report. It confirms what was visually apparent from the photo-documentation on our website. Her biopsy was free of cancer cells and she will not need any surgical procedure. Nevertheless, the patient will continue with her self-administered topical application of extracts for a while longer to minimize any chance of any surviving cancer cells in areas beyond what was biopsied.

Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D., stated, “Squamous cell carcinomas have a much greater invasive potential than is typical of basal cell carcinomas. Photo-documentation of topical cannabis extract treatments of patient #2 and patient #3 dramatically demonstrate how the treatment appear to extrude the subcutaneous tumor to the surface as the killing and subsequent healing proceeds. Patient #3 reports continued progress as his tumors appear to shrink and the pain levels continue to improve. The patient’s wife commented that about 75% of the large tumor mass is gone. We will continue with ‘live updates’ as new pictures and physician reports are made available to us.”

You can view the patient’s photographs during the treatment process, as well as the full biopsy report from the physician, on the Cannabis Science website www.cannabisscience.com. Click the button “View Images of 2nd Self-Medicated Patient & The Apparent Success” to view the full biopsy report, photos and additional information.

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888
President & CEO
info@cannabisscience.com
www.cannabisscience.com
or
Robert Kane, 1-561-234-6929
VP Investor Relations
rkane@cannabisscience.com
info@cannabisscience.com
www.cannabisscience.com

View full post on News Releases

Cannabis Science Continues Forward with FDA IND Process as Patients Report Successful Cancer Treatments

April 2, 2012

DENVER–(BUSINESS WIRE)– Cannabis Science, Inc. (OTCBB: CBIS.OB – News) a pioneering U.S. biotech company developing cannabis pharmaceutical and over the counter nutraceutical products, is pleased to report it is moving forward with its FDA IND process. We have kept the public up to date with self-medicated skin cancer patients who are benefiting from topical cannabis-based extracts. These patients have experienced dramatic reduction in tumor burden and for some apparent eradication of their skin cancers.

The Company has received from our consultants its initial review for Pre-IND preparation work and for the submitting Pre-IND request letter. With several questions answered and confirmed for the Company, the Company will sign off and its’ consultants will prepare the Pre-IND meeting submission package.

The Company and its FDA specialists understand the regulatory strategy and guidance, the timelines for preparation, and the conduct required at the FDA pre-IND meeting. These timelines are determined by FDA policy with the aim of facilitating the application process. The budget review was positive and realistic consisting of estimates of consultant hours, costs, activities, recurring activities, travel and other direct expenses.

Federal law requires that a marketing application for a new drug be approved before the drug can be transported or distributed over state lines. A sponsor will want to ship the investigational drug to clinical investigators, and therefore must seek an exemption from any existing legal restrictions. When a drug is in preclinical development, the sponsor’s primary goal is to make sure the product is safe for initial testing on humans and that the pharmacological activity justifies commercial development. When a product is determined to be a viable candidate for further development, the sponsor collects data and information necessary to establish that the product will not harm humans or exposes them to unreasonable risks when used in limited clinical studies.

Cannabis Science and cancer patients look forward to benefiting from the company’s formulations when they become available on the mainstream market. Cannabis Science is confident as to the efficacy of its products since they are currently used by patients on a limited intra-state basis.

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888
President & CEO
info@cannabisscience.com
www.cannabisscience.com
or
Robert Kane, 1-561-234-6929
VP Investor Relations
rkane@cannabisscience.com
info@cannabisscience.com
www.cannabisscience.com

View full post on News Releases

Posetite : skajvok3r.blogspot.com